Nimish Valvi

发表

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

S. Schrag, K. Natarajan, S. Grannis, 2021, The New England journal of medicine.

COVID-19 Diagnosis and Risk of Death Among Adults With Cancer in Indiana: Retrospective Cohort Study

D. Haggstrom, B. Dixon, G. Bakoyannis, 2022, JMIR cancer.

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

William F. Fadel, Sarah E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.

S. E. Reese, M. Stockwell, R. Link-Gelles, 2023, Pediatrics.

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

William F. Fadel, S. E. Reese, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, American Journal of Transplantation.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2022, medRxiv.

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, JAMA network open.

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, BMJ.

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study

R. Link-Gelles, P. Embí, K. Natarajan, 2023, Lancet regional health. Americas.

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.

William F. Fadel, S. E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021

S. E. Reese, C. Mcevoy, S. Schrag, 2021, American Journal of Transplantation.

The synchronicity of COVID-19 disparities: Statewide epidemiologic trends in SARS-CoV-2 morbidity, hospitalization, and mortality among racial minorities and in rural America

P. Embí, S. Grannis, B. Dixon, 2021, PloS one.

Medicaid Expansion and Breast Cancer Screening in Appalachia and Non-Appalachia, United States, BRFSS 2003 to 2015

T. Akinyemiju, Nimish Valvi, Neomi Vin-Raviv, 2019, Cancer control : journal of the Moffitt Cancer Center.

Investigating the Relation between Electronic Cigarette Use and Sleep Duration in Kentucky Using the BRFSS, 2016–2017

W. Christian, C. J. Walker, N. Valvi, 2023, Southern medical journal.

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022

William F. Fadel, C. Mcevoy, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Examining Adult E-cigarette Use in Kentucky and Its Appalachian Region Using the Behavioral Risk Factor Surveillance System, 2016-2017

W. Christian, C. J. Walker, N. Valvi, 2021, Public health reports.